Lumanity expert discussion – recorded at BIO-EUROPE, Stockholm
While biotechs are developing many complex and innovative new platforms, Lumanity research shows that large pharma companies are increasingly only willing to invest in commercially proven solutions.
In this video recorded at BIO-EUROPE, our experts Alex Fink and Ed Saltzman take a few minutes to share their views on why biopharma must better prepare for commercialization, even if the aim is to seek partnerships. They tackle common myths surrounding this topic, and offer practical guidance on how teams can effectively approach commercial thinking.
Read our White Paper: Biopharma Dealmaking and Commercialization Readiness here.
“Biotech has been massively good at innovating, but they have not done a good job at getting their innovation to patients. And that’s what this is all about in the end.”
Ed Saltzman, Senior Strategic Advisor
